Clearing the path for MPN therapy monitoring

Ruben A. Mesa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In this issue of Blood, Takahashi and colleagues have helped clarify the validity of using peripheral blood for monitoring the JAK2-V617F allele burden among the myeloproliferative neoplasms.1 The understanding of the BCR-ABL-negative MPNs of essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) encountered a true watershed in 2005 with the discovery of the JAK2 V617F mutation.2 This latter discovery had an incredible impact on many levels, inspiring the hematology research community to investigate the pathophysiology of these MPNs as well as begin development of new MPNdirected therapies. Subsequently, multiple additional mutations in the molecular pathways that can be involved with the pathophysiology of MPNs include the JAK2 Exon 12; mutations in MPL, ASXL1, IDH1/2, EZH2; and deletions in TET2.3 Although many of these additional molecular and genetic discoveries may have important implications in terms of the behavior of subsets of myeloproliferative neoplasia of MPNs, they may have prognostic implications particular to the area of leukemic transformation, but most of these remain relatively low-prevalence mutations; now almost 9 years after the discovery of the JAK2 V617F, this mutation remains by far the most prevalent, widely tested, and impactful of the MPN mutations.

Original languageEnglish (US)
Pages (from-to)3704-3705
Number of pages2
JournalBlood
Volume122
Issue number23
DOIs
StatePublished - Nov 28 2013

Fingerprint

Blood
Mutation
Monitoring
Watersheds
Exons
Essential Thrombocythemia
Therapeutics
Polycythemia Vera
Primary Myelofibrosis
Hematology
Molecular Biology
Alleles
Research
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Clearing the path for MPN therapy monitoring. / Mesa, Ruben A.

In: Blood, Vol. 122, No. 23, 28.11.2013, p. 3704-3705.

Research output: Contribution to journalArticle

Mesa, Ruben A. / Clearing the path for MPN therapy monitoring. In: Blood. 2013 ; Vol. 122, No. 23. pp. 3704-3705.
@article{739ccf4bf2754515934b6404ea64b1e7,
title = "Clearing the path for MPN therapy monitoring",
abstract = "In this issue of Blood, Takahashi and colleagues have helped clarify the validity of using peripheral blood for monitoring the JAK2-V617F allele burden among the myeloproliferative neoplasms.1 The understanding of the BCR-ABL-negative MPNs of essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) encountered a true watershed in 2005 with the discovery of the JAK2 V617F mutation.2 This latter discovery had an incredible impact on many levels, inspiring the hematology research community to investigate the pathophysiology of these MPNs as well as begin development of new MPNdirected therapies. Subsequently, multiple additional mutations in the molecular pathways that can be involved with the pathophysiology of MPNs include the JAK2 Exon 12; mutations in MPL, ASXL1, IDH1/2, EZH2; and deletions in TET2.3 Although many of these additional molecular and genetic discoveries may have important implications in terms of the behavior of subsets of myeloproliferative neoplasia of MPNs, they may have prognostic implications particular to the area of leukemic transformation, but most of these remain relatively low-prevalence mutations; now almost 9 years after the discovery of the JAK2 V617F, this mutation remains by far the most prevalent, widely tested, and impactful of the MPN mutations.",
author = "Mesa, {Ruben A.}",
year = "2013",
month = "11",
day = "28",
doi = "10.1182/blood-2013-10-529990",
language = "English (US)",
volume = "122",
pages = "3704--3705",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "23",

}

TY - JOUR

T1 - Clearing the path for MPN therapy monitoring

AU - Mesa, Ruben A.

PY - 2013/11/28

Y1 - 2013/11/28

N2 - In this issue of Blood, Takahashi and colleagues have helped clarify the validity of using peripheral blood for monitoring the JAK2-V617F allele burden among the myeloproliferative neoplasms.1 The understanding of the BCR-ABL-negative MPNs of essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) encountered a true watershed in 2005 with the discovery of the JAK2 V617F mutation.2 This latter discovery had an incredible impact on many levels, inspiring the hematology research community to investigate the pathophysiology of these MPNs as well as begin development of new MPNdirected therapies. Subsequently, multiple additional mutations in the molecular pathways that can be involved with the pathophysiology of MPNs include the JAK2 Exon 12; mutations in MPL, ASXL1, IDH1/2, EZH2; and deletions in TET2.3 Although many of these additional molecular and genetic discoveries may have important implications in terms of the behavior of subsets of myeloproliferative neoplasia of MPNs, they may have prognostic implications particular to the area of leukemic transformation, but most of these remain relatively low-prevalence mutations; now almost 9 years after the discovery of the JAK2 V617F, this mutation remains by far the most prevalent, widely tested, and impactful of the MPN mutations.

AB - In this issue of Blood, Takahashi and colleagues have helped clarify the validity of using peripheral blood for monitoring the JAK2-V617F allele burden among the myeloproliferative neoplasms.1 The understanding of the BCR-ABL-negative MPNs of essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) encountered a true watershed in 2005 with the discovery of the JAK2 V617F mutation.2 This latter discovery had an incredible impact on many levels, inspiring the hematology research community to investigate the pathophysiology of these MPNs as well as begin development of new MPNdirected therapies. Subsequently, multiple additional mutations in the molecular pathways that can be involved with the pathophysiology of MPNs include the JAK2 Exon 12; mutations in MPL, ASXL1, IDH1/2, EZH2; and deletions in TET2.3 Although many of these additional molecular and genetic discoveries may have important implications in terms of the behavior of subsets of myeloproliferative neoplasia of MPNs, they may have prognostic implications particular to the area of leukemic transformation, but most of these remain relatively low-prevalence mutations; now almost 9 years after the discovery of the JAK2 V617F, this mutation remains by far the most prevalent, widely tested, and impactful of the MPN mutations.

UR - http://www.scopus.com/inward/record.url?scp=84891096633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891096633&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-10-529990

DO - 10.1182/blood-2013-10-529990

M3 - Article

C2 - 24288406

AN - SCOPUS:84891096633

VL - 122

SP - 3704

EP - 3705

JO - Blood

JF - Blood

SN - 0006-4971

IS - 23

ER -